Male breast cancer in Northern Tanzania: Clinicopathology and predictors of two-year survival (2016–2022)
5 affiliations
- 1Department of General Surgery, KCMC University, Moshi, Tanzania
- 2Department of General Surgery, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 3Kilimanjaro Clinical Research Institute, Moshi, Tanzania
- 4Cancer Care Centre, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
- 5Department of Pathology, Kilimanjaro Christian Medical Centre, Moshi, Tanzania
Abstract
Background: Male breast cancer (BC) is rare, accounting to approximately 1% of all breast cancers worldwide. Patients often present with advanced disease, contributing to poor outcomes. This study aimed to estimate two-year overall survival (OS) and identify clinicopathological and health-system–related predictors of survival among men with breast cancer treated at Kilimanjaro Christian Medical Centre (KCMC). Methods: A retrospective cohort study was conducted among 55 histologically confirmed male BC patients managed at KCMC between 2016 and 2022. The primary outcome was two-year overall survival, defined as time from histological diagnosis to death from any cause or censoring at two years. The dependent variables were clinical and pathological factors and the key independent variable was overall survival (OS). Descriptive statistics summarized participants characteristics. Kaplan–Meier curves, log-rank and Cox proportional hazards regression were used to estimate the OS and the factors associated. A p-value <0.05 was considered statistically significant. Results: The mean age at diagnosis was 62.2 ± 14.3 years, with most patients (54.6%) aged between 50–70 years. Over half (52.7%) presented with stage III or IV disease, and 21.8% had distant metastasis. Invasive ductal carcinoma (IDC) was the predominant histological subtype (85.5%), and luminal B was the most common molecular profile (23.6%). Surgery was performed in 60% of patients, chemotherapy in 47.3%, hormonal therapy in 30.9%, and radiotherapy in only 9.1%. The overall two-year survival rate was 67.3%. Independent predictors of poor survival included age > 70 years (p = 0.009), stage IV disease (p = 0.005), delayed receipt of histopathological results (> 2 weeks), delayed surgery (>6 weeks), and non-receipt of hormonal therapy or radiotherapy. Conclusion: Male BC in Northern Tanzania remains a disease for older who frequently present with advanced-stages. Two-year overall survival remains suboptimal and is strongly influenced by advanced disease stage, older age, diagnostic and treatment delays, and limited access to adjuvant therapies. Strengthening early diagnosis, timely pathology reporting, and access to radiotherapy and hormonal therapy may substantially improve outcomes.
Related
- Childhood burkitt lymphoma: treatment outcomes, survival, and mortality predictors at two tertiary hospitals in Tanzania
- Characterizing geospatial access to comprehensive breast cancer services in Northern Tanzania
- Survival Status and Predictors of Mortality Among Women With Breast Cancer in Southern Ethiopia: A Retrospective Cohort Study
- The Long Road to Care: A Mixed Methods Analysis of Referral Delays for Pediatric Injury Patients in Northern Tanzania
- Suspected Pentalogy of Cantrell With Ectopia Cordis in a Newborn: Diagnostic and Management Challenges in a Low Resource Setting in Northern Tanzania.
BibTeX
@article{emaely2026male,
title = {{Male breast cancer in Northern Tanzania: Clinicopathology and predictors of two-year survival (2016–2022)}},
author = {Timon Stephen Emaely and Alex Mremi and Elizabeth F. Msoka and Rebeca Mutashobya and Blandina T. Mmbaga and Kondo Chilonga},
journal = {PLOS One},
year = {2026},
month = nov,
doi = {10.1371/journal.pone.0361615},
url = {https://doi.org/10.1371/journal.pone.0361615},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Male breast cancer in Northern Tanzania: Clinicopathology and predictors of two-year survival (2016–2022)
AU - Timon Stephen Emaely
AU - Alex Mremi
AU - Elizabeth F. Msoka
AU - Rebeca Mutashobya
AU - Blandina T. Mmbaga
AU - Kondo Chilonga
PY - 2026
DA - 2026/11/06
JO - PLOS One
DO - 10.1371/journal.pone.0361615
UR - https://doi.org/10.1371/journal.pone.0361615
AB - Background: Male breast cancer (BC) is rare, accounting to approximately 1% of all breast cancers worldwide. Patients often present with advanced disease, contributing to poor outcomes. This study aimed to estimate two-year overall survival (OS) and identify clinicopathological and health-system–related predictors of survival among men with breast cancer treated at Kilimanjaro Christian Medical Centre (KCMC). Methods: A retrospective cohort study was conducted among 55 histologically confirmed male BC patients managed at KCMC between 2016 and 2022. The primary outcome was two-year overall survival, defined as time from histological diagnosis to death from any cause or censoring at two years. The dependent variables were clinical and pathological factors and the key independent variable was overall survival (OS). Descriptive statistics summarized participants characteristics. Kaplan–Meier curves, log-rank and Cox proportional hazards regression were used to estimate the OS and the factors associated. A p-value <0.05 was considered statistically significant. Results: The mean age at diagnosis was 62.2 ± 14.3 years, with most patients (54.6%) aged between 50–70 years. Over half (52.7%) presented with stage III or IV disease, and 21.8% had distant metastasis. Invasive ductal carcinoma (IDC) was the predominant histological subtype (85.5%), and luminal B was the most common molecular profile (23.6%). Surgery was performed in 60% of patients, chemotherapy in 47.3%, hormonal therapy in 30.9%, and radiotherapy in only 9.1%. The overall two-year survival rate was 67.3%. Independent predictors of poor survival included age > 70 years (p = 0.009), stage IV disease (p = 0.005), delayed receipt of histopathological results (> 2 weeks), delayed surgery (>6 weeks), and non-receipt of hormonal therapy or radiotherapy. Conclusion: Male BC in Northern Tanzania remains a disease for older who frequently present with advanced-stages. Two-year overall survival remains suboptimal and is strongly influenced by advanced disease stage, older age, diagnostic and treatment delays, and limited access to adjuvant therapies. Strengthening early diagnosis, timely pathology reporting, and access to radiotherapy and hormonal therapy may substantially improve outcomes.
SN - 1932-6203
ER -